Research ArticleNuclear Neurology
Iodine-123-β-CIT and Iodine-123-FPCIT SPECT Measurement of Dopamine Transporters in Healthy Subjects and Parkinson's Patients
John P. Seibyl, Kenneth Marek, Kimberly Sheff, Sami Zoghbi, Ronald M. Baldwin, Dennis S. Charney, Christopher H. van Dyck and Robert B. Innis
Journal of Nuclear Medicine September 1998, 39 (9) 1500-1508;
John P. Seibyl
Kenneth Marek
Kimberly Sheff
Sami Zoghbi
Ronald M. Baldwin
Dennis S. Charney
Christopher H. van Dyck
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Iodine-123-β-CIT and Iodine-123-FPCIT SPECT Measurement of Dopamine Transporters in Healthy Subjects and Parkinson's Patients
John P. Seibyl, Kenneth Marek, Kimberly Sheff, Sami Zoghbi, Ronald M. Baldwin, Dennis S. Charney, Christopher H. van Dyck, Robert B. Innis
Journal of Nuclear Medicine Sep 1998, 39 (9) 1500-1508;
Iodine-123-β-CIT and Iodine-123-FPCIT SPECT Measurement of Dopamine Transporters in Healthy Subjects and Parkinson's Patients
John P. Seibyl, Kenneth Marek, Kimberly Sheff, Sami Zoghbi, Ronald M. Baldwin, Dennis S. Charney, Christopher H. van Dyck, Robert B. Innis
Journal of Nuclear Medicine Sep 1998, 39 (9) 1500-1508;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts
- A staged screening protocol identifies people with biomarkers related to neuronal alpha-synuclein disease
- Responsivity of the striatal dopamine system to methylphenidate - a within-subject I-123-ss-CIT-SPECT study in children and adolescents with Attention-Deficit/Hyperactivity Disorder
- An Anthropomorphic Phantom Study of Brain Dopamine Transporter SPECT Images Obtained Using Different SPECT/CT Devices and Collimators
- Imaging prodromal Parkinson disease: The Parkinson Associated Risk Syndrome Study
- Safety Analysis of 10 Clinical Trials and for 13 Years After First Approval of Ioflupane 123I Injection (DaTscan)
- Assessing the Optimal Time Point for the Measurement of Extrastriatal Serotonin Transporter Binding with 123I-FP-CIT SPECT in Healthy, Male Subjects
- SNM Practice Guideline for Dopamine Transporter Imaging with 123I-Ioflupane SPECT 1.0
- Serotonin Transporters in Dopamine Transporter Imaging: A Head-to-Head Comparison of Dopamine Transporter SPECT Radioligands 123I-FP-CIT and 123I-PE2I
- The scientific and clinical basis for the treatment of Parkinson disease (2009)
- Reproducibility of a Standardized Quantitative Analysis Using Fixed Regions of Interest to Differentiate Movement Disorders on 123I-FP-CIT SPECT
- Pharmacological Characterization of (E)-N-(4-Fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4'-tolyl)nortropane (LBT-999) as a Highly Promising Fluorinated Ligand for the Dopamine Transporter
- How useful is [123I]{beta}-CIT SPECT in clinical practice?
- Sensitivity and Specificity of 99mTc-TRODAT-1 SPECT Imaging in Differentiating Patients with Idiopathic Parkinson's Disease from Healthy Subjects
- Reproducibility of 99mTc-TRODAT-1 SPECT Measurement of Dopamine Transporters in Parkinson's Disease
- Dosimetry of the Dopamine Transporter Radioligand 18F-FPCIT in Human Subjects
- Quantification of Dopamine Transporter by 123I-PE2I SPECT and the Noninvasive Logan Graphical Method in Parkinson's Disease
- An algorithm (decision tree) for the management of Parkinson's disease (2001):: Treatment
- Brain SPECT in Neurology and Psychiatry
- Structural Changes of the Substantia Nigra in Parkinson's Disease as Revealed by MR Imaging
- Parkinson's disease: a novel MRI method for determining structural changes in the substantia nigra
- Usefulness of a dopamine transporter PET ligand [18F]beta -CFT in assessing disability in Parkinson's disease